NEW YORK (GenomeWeb) – Swift Biosciences announced today that it has raised $12.2 million through a Series D round of financing.
The round was led by venture capital firm Arboretum Ventures and included existing Swift investors. The company, which develops next-generation sequencing sample prep technologies, said that it intends to use the funding to expand its global commercial channels, as well as enhance its manufacturing and operation capabilities.